Santhera Pharmaceuticals announces that the Department of Health of Hong Kong, China, has approved AGAMREE® (vamorolone) for use in patients aged 4 years and older.
- Follow Us -
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
|
Less than 1 min read
|
Updated:
Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment.
Disclaimer: No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.